Abstract
The overactive bladder syndrome and the neurogenic detrusor overactivity figure among the most impacting voiding dysfunctions with a high global prevalence and negative impacts on quality of life. Despite such urinary disorders being easily diagnosed, often based exclusively on clinical data, a large number of people complaining of urgency, frequency, nocturia and, in many cases, urinary incontinence, have their urinary condition neglected. The first line treatment with oral anticholinergics presents a high rate of dropouts over a few months of use, due absence of success or the adverse events frequently observed with this therapy. Intradetrusor botulinum toxin injection was initially used for patients with spinal cord injury and multiple sclerosis, nearly 15 years ago. Its successful results led to the injections in detrusor of botulinum toxin also in refractory idiopathic overactive bladder.
Keywords: Anticholinergics, botulinum toxin, intravesical injection, neurogenic bladder, overactive bladder, overactive detrusor function.
Reviews on Recent Clinical Trials
Title:Overactive Bladder Syndrome, Detrusor Overactivity and the Botulinum Toxin
Volume: 10 Issue: 2
Author(s): Jose Carlos Truzzi
Affiliation:
Keywords: Anticholinergics, botulinum toxin, intravesical injection, neurogenic bladder, overactive bladder, overactive detrusor function.
Abstract: The overactive bladder syndrome and the neurogenic detrusor overactivity figure among the most impacting voiding dysfunctions with a high global prevalence and negative impacts on quality of life. Despite such urinary disorders being easily diagnosed, often based exclusively on clinical data, a large number of people complaining of urgency, frequency, nocturia and, in many cases, urinary incontinence, have their urinary condition neglected. The first line treatment with oral anticholinergics presents a high rate of dropouts over a few months of use, due absence of success or the adverse events frequently observed with this therapy. Intradetrusor botulinum toxin injection was initially used for patients with spinal cord injury and multiple sclerosis, nearly 15 years ago. Its successful results led to the injections in detrusor of botulinum toxin also in refractory idiopathic overactive bladder.
Export Options
About this article
Cite this article as:
Truzzi Carlos Jose, Overactive Bladder Syndrome, Detrusor Overactivity and the Botulinum Toxin, Reviews on Recent Clinical Trials 2015; 10 (2) . https://dx.doi.org/10.2174/1574887110666150416105200
DOI https://dx.doi.org/10.2174/1574887110666150416105200 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Activation and Activators of TRPV1 and Their Pharmaceutical Implication
Current Pharmaceutical Design Commentary-1 Research Highlights (Never Underestimate the Power of Adenosine in Multiple Sclerosis)
CNS & Neurological Disorders - Drug Targets Functional Domains of Aquaporin-1: Keys to Physiology, and Targets for Drug Discovery
Current Pharmaceutical Design Therapeutic Potential of Ferulic Acid in Alzheimer's Disease
Current Drug Delivery Peptide modules for overcoming barriers of nucleic acids transport to cells
Current Topics in Medicinal Chemistry Therapeutic Medical Hypothermia-A Multispecialty Approach
Recent Patents on Cardiovascular Drug Discovery Investigation of the Effect of Operating Room Environment and Cesarean Section Orientation on Physiological Parameters (BP, Heart Rate, Respiration) in Candidates for Cesarean Section in Shiraz: A Clinical Trial Study
Current Women`s Health Reviews Antagonists of the Vasopressin V1 Receptor and of the β<sub>1</sub>-Adrenoceptor Inhibit Cytotoxic Brain Edema in Stroke by Effects on Astrocytes-but the Mechanisms Differ
Current Neuropharmacology Nitrone Derivatives as Therapeutics: From Chemical Modification to Specific-targeting
Current Topics in Medicinal Chemistry Drug Targets of Migraine and Neuropathy: Treatment of Hyperexcitability
CNS & Neurological Disorders - Drug Targets Membrane Localization of Estrogen Receptors
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Sex Hormones and their Analogues in Neuroimmune Biology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Animal Models in Neurology: Drawbacks and Opportunities
Current Pharmaceutical Design Inhibition of the Function of TRPV1-Expressing Nociceptive Sensory Neurons by Somatostatin 4 Receptor Agonism: echanism and Therapeutical Implications
Current Topics in Medicinal Chemistry Calcium Homeostasis and Kinetics in Heart Failure
Medicinal Chemistry HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy Cell Death in Mammalian Development
Current Pharmaceutical Design Recent Patents on Cell-based Approaches to Collagen Enrichment and Repair
Recent Patents on Regenerative Medicine Targeting Neuropathic Pain: Pathobiology, Current Treatment and Peptidomimetics as a New Therapeutic Opportunity
Current Medicinal Chemistry Gene Therapy Strategies Towards Immune Tolerance to Treat the Autoimmune Diseases
Current Gene Therapy